Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Adenocarcinoma × apatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4 Stomach Neoplasms 3 Triple Negative Breast Neoplasms 2 Advanced Solid Tumor 2 Advanced Cancer 2 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Mouth Neoplasms 1 Extensive Stage Small Cell Lung Cancer 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Biliary Tract Malignancies 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Fluorouracil 9 Gemcitabine 7 pembrolizumab 6 Irinotecan 6 Paclitaxel 5 Leucovorin 5 Carboplatin 5 Nivolumab 4 Cisplatin 4 130-nm albumin-bound paclitaxel 4 Radiosurgery 3 Pemetrexed 3 Oxaliplatin 3 Albumin-Bound Paclitaxel 3 vandetanib 2 spartalizumab 2 selinexor 2 osimertinib 2 folfirinox 2 Taxes 2 Ramucirumab 2 Radiation 2 Docetaxel 2 Cyclophosphamide 2 Capecitabine 2 Bevacizumab 2 zolbetuximab 1 trastuzumab deruxtecan 1 trametinib 1 tofacitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407976 2020-07-15

APPEASE

University of Utah

Phase 1 Terminated

Adenocarcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡